Trials / Completed
CompletedNCT02614716
A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's Syndrome
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to learn more about the safety and side effects of the study drug known as LY3090106 in participants with Sjögren's Syndrome (SS). The study will also evaluate how much of the study drug gets into the blood stream and how long it takes the body to remove it.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3090106 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2015-12-10
- Primary completion
- 2018-09-05
- Completion
- 2018-09-05
- First posted
- 2015-11-25
- Last updated
- 2018-12-11
Locations
7 sites across 4 countries: United States, Bulgaria, Georgia, Romania
Source: ClinicalTrials.gov record NCT02614716. Inclusion in this directory is not an endorsement.